The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Series F - II | Alive

Total Raised


Last Raised

$12M | 9 yrs ago

About Zyomyx

Zyomyx a privately held diagnostics company based in Fremont, California, is an innovator in the development and commercialization of diagnostic platforms. The Zyomyx product development infrastructure and suite of proprietary assay and surface technologies are ideally suited for the development of affordable, disposable point-of-care diagnostic products, designed to increase access to testing. Zyomyx's first product is an advanced but simple and inexpensive CD4 T-cell point-of-care test that will be launched globally and is configured to meet the needs of developing countries.

Zyomyx Headquarter Location

6519 Dumbarton Circle

Fremont, California, 94555,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Zyomyx

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Zyomyx is included in 1 Expert Collection, including Health Monitoring & Diagnostics.


Health Monitoring & Diagnostics

701 items

Companies developing technology to facilitate near-patient and point-of-care (POC) in vitro diagnostic testing. Companies tagged as #NearPatient&POCTesting

Zyomyx Patents

Zyomyx has filed 7 patents.

patents chart

Application Date

Grant Date


Related Topics




Immunology, Immune system, Clusters of differentiation, Radiation therapy, Blood tests


Application Date


Grant Date



Related Topics

Immunology, Immune system, Clusters of differentiation, Radiation therapy, Blood tests



Latest Zyomyx News

Protein Biochip Market Witness Steady Expansion During 2019-2025 | Zyomyx, Randox, Orlaprotein, GE Healthcare, Thermo Fisher, Scienion AG and Others

Feb 17, 2020

The report on the global “ Protein Biochip market ” studies the existing as well as the future visions of the global Protein Biochip market. It includes a detailed outline of the global Protein Biochip market along with market pictures. Also, it offers complete data of the various segments in the global Protein Biochip market study. The report analyzes each segment of the global Protein Biochip market on the basis of application, end-user, and region. In addition, it also highlights the dominating players in the market joined with their market share. The well-established players in the market are Zyomyx, Randox, Orlaprotein, GE Healthcare, Thermo Fisher, Scienion AG, Horiba. Click here to access the report: The global Protein Biochip market report is assessed on the basis of revenue (USD Million) and the size of the global Protein Biochip market. It analyzes various market dynamics such as drivers, limitations, and opportunities impacting on the Protein Biochip market. It also predicts the influence of these key elements on the growth of the Protein Biochip market in the upcoming period. Through the market share study, the competitive scenario of the dominating market players is assessed. The report demonstrates the present trends and strategies adopted by the most leading players in the market. This analysis helps the leading as well as new market players to strengthen their positions and enhance their share in the global Protein Biochip market. The data demonstrated in the global Protein Biochip market research report helps the market players to stand firmly in the global Protein Biochip market. Read Detailed Index of full Research Study at:: The research report includes the features contributing to and influencing the expansion of the global Protein Biochip market. It projects the market assessment for the predicted time. The report furthermore states the recent market trends and the key prospects contributing to the growth of the Protein Biochip market in the future time. Moreover, the major product type and segments Active Chip, Passive Chip, Protein Biochip along with the sub-segments Medical Care, Laboratory, Others of the global market are covered in the report. On a regional basis, the market is categorized into five regions such as North America, Latin America, Middle & East Africa, Asia Pacific, and Europe. The report also demonstrates the impact of Porter’s Five Forces on the global Protein Biochip market. The report covers important Protein Biochip market data in the form of tables, graphics, and pictures. There are 15 Chapters to display the Global Protein Biochip market Chapter 1, Definition, Specifications and Classification of Protein Biochip, Applications of Protein Biochip, Market Segment by Regions; Chapter 2, Manufacturing Cost Structure, Raw Material, and Suppliers, Manufacturing Process, Industry Chain Structure; Chapter 3, Technical Data and Manufacturing Plants Analysis of Protein Biochip, Capacity and Commercial Production Date, Manufacturing Plants Distribution, R&D Status and Technology Source, Raw Materials Sources Analysis; Chapter 4, Overall Market Analysis, Capacity Analysis (Company Segment), Sales Analysis (Company Segment), Sales Price Analysis (Company Segment); Chapter 5 and 6, Regional Market Analysis that includes the United States, China, Europe, Japan, Korea & Taiwan, Protein Biochip Segment Market Analysis (by Type); Chapter 7 and 8, The Protein Biochip Segment Market Analysis (by Application) Major Manufacturers Analysis of Protein Biochip; Chapter 9, Market Trend Analysis, Regional Market Trend, Market Trend by Product Type Active Chip, Passive Chip, Protein Biochip, Market Trend by Application Medical Care, Laboratory, Others; Chapter 10, Regional Marketing Type Analysis, International Trade Type Analysis, Supply Chain Analysis; Chapter 11, The Consumers Analysis of Global Protein Biochip; Chapter 12, Protein Biochip Research Findings and Conclusion, Appendix, methodology and data source; Chapter 13, 14 and 15, Protein Biochip sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source. Enquire Here Get customization & check discount for report @: Reasons for Buying Protein Biochip Market This report provides pin-point analysis for changing competitive dynamics It provides a forward-looking perspective on different factors driving or restraining the market growth It provides a six-year forecast assessed on the basis of how the market is predicted to grow It helps in understanding the key product segments and their future It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors It helps in making informed business decisions by having complete insights of market and by making an in-depth analysis of market segments Thanks for reading this article; you can also get individual chapter wise section or region wise report versions like North America, Europe or Asia.

  • When was Zyomyx founded?

    Zyomyx was founded in 1998.

  • Where is Zyomyx's headquarters?

    Zyomyx's headquarters is located at 6519 Dumbarton Circle, Fremont.

  • What is Zyomyx's latest funding round?

    Zyomyx's latest funding round is Series F - II.

  • How much did Zyomyx raise?

    Zyomyx raised a total of $115.79M.

  • Who are the investors of Zyomyx?

    Investors of Zyomyx include Mylan, Bill & Melinda Gates Foundation, Tekla Capital Management, Alloy Ventures, Credit Suisse First Boston and 16 more.

  • Who are Zyomyx's competitors?

    Competitors of Zyomyx include Pepscan, HTG Molecular Diagnostics, BioVidria, Protein Discovery, Decision Biomarkers and 12 more.

You May Also Like


PolyAn Molecular Surface Engineering: fluorescent encoded polymer microspheres (beads), microarray slides and membranes for Pervaporation and organophilic Nanofiltration

Biocolor Logo

Biocolor offers assay kits (eg Collagen and Elastin) for tissue culture laboratories.

Solidus Biosciences Logo
Solidus Biosciences

Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.

Shamrock Structures Logo
Shamrock Structures

Shamrock Structures is a structural proteomics company focused on assisting pharmaceutical and biotechnology clients reduce the time it takes to advance from protein targets to drugs by offering integrated services in structural proteomics including protein cloning, expression, purification and crystallization.


SideroGen, Inc. is focused on the development and manufacture of biomolecule purification products for applications in the fields of forensic science and clinical genomics. These products will be developed for processing very small samples, common to forensic science and cancer diagnostics. The core technology for these products is based on inert ferro-ceramic, paramagnetic particles of compositions that are specifically designed to be compatible with downstream DNA and protein analysis. This technology and its uses are exclusively owned and were developed by SideroGen, Inc.

Sistemic Logo

SistemRNA is a healthcare company developing a microRNA-based platform that screens compound databases against the microRNA expression profiles of leading drugs, to find compounds with similar profiles. Per Sistemic, this process generates information on biological differences, mechanism of action and potential new targets.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.